ArticleMolecular & cellular oncology2017
The enigma of RIPK1 in the liver: More than just a kinase.
Article in Molecular & cellular oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The Inhibition of Bruton Tyrosine Kinase Alleviates Acute Liver Failure via Downregulation of NLRP3 Inflammasome.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- RIP1 kinase activity promotes steatohepatitis through mediating cell death and inflammation in macrophages.Cell death and differentiation · 2021Article
- JNK signaling prevents biliary cyst formation through a CASPASE-8-dependent function of RIPK1 during aging.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- PIDDosome-induced p53-dependent ploidy restriction facilitates hepatocarcinogenesis.EMBO reports · 2020Article
- Effects of BTK signalling in pathogenic microorganism infections.Journal of cellular and molecular medicine · 2019Review
- Article
- Apoptosis and necroptosis in the liver: a matter of life and death.Nature reviews. Gastroenterology & hepatology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Receptor interacting protein kinase 1 (RIPK1) represents a key molecule in cell death. Here, we discuss our recent data on RIPK1 in liver injury and hepatocellular carcinoma development and put these into relation to previous experimental findings to underpin that it exerts opposing kinase-dependent and kinase independent functions in liver cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.